MedTrace Logo

Intensive Lipid-lowering in Patients With STEMI and NSTEMI (Germany on Target)

NCT05587621 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2024-03-07

No results posted yet for this study

Summary

Intensive Lipid-Lowering Therapy guided by a cloud-based Software System (CLIMEDO GmbH) improves (European Society of Cardiolofgy/European Atherosclerosis Society) ESC/EAS-guideline recommended LDL-cholesterol target attainment and adherence in patients with ST-Elevation Myocardial (STEMI) and Non-ST-Elevation Myocardial Infarctions (NSTEMI).

Conditions

  • ST Elevation Myocardial Infarction
  • Non-ST Elevation Myocardial Infarction
  • LDL-cholesterol

Interventions

DRUG

statins, ezetimibe, bempedoic acid, evolocumab, alirocumab, inclisiran

dietary advice for low cholesterol food

Sponsors & Collaborators

  • Jena University Hospital

    lead OTHER

Principal Investigators

  • Oliver Weingärtner, MD · Jena University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-01
Primary Completion
2026-04-30
Completion
2026-12-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05587621 on ClinicalTrials.gov